Validation of a primary care electronic medical records case definition for eczema: retrospective cross-sectional study

Simple item page
dc.contributor.authorStirton, Hannah
dc.contributor.authorKosowan, Leanne
dc.contributor.authorAbrams, Elissa M.
dc.contributor.authorProtudjer, Jennifer L.
dc.contributor.authorQueenan, John
dc.contributor.authorSinger, Alexander
dc.date.accessioned2023-06-01T17:38:42Z
dc.date.available2023-06-01T17:38:42Z
dc.date.issued2023-05-28
dc.date.updated2023-06-01T03:27:53Z
dc.description.abstractAbstract Background To validate case definitions for eczema using primary care Electronic Medical Record (EMR) data from the Canadian Primary Care Sentential Surveillance Network (CPCSSN). Methods This study used EMR data from 1,574 primary care providers in seven Canadian provinces, representing 689,301 patients. Using a subset of patient records seven medical students or family medicine residents created a reference set of 1,772 patients. A total of 23 clinician-informed case definitions were validated against the reference. We assessed agreement using sensitivity (SE), specificity (SP), positive predictive value (PPV), negative predictive value (NPV) and overall accuracy. The case definitions with the best agreement statistics were deployed to estimate the prevalence of eczema in the CPCSSN. Results Case definition 1 had the highest SE (92.1%,85.0-96.5) but a lower SP (88.5%,86.7–90.1) and PPV (36.6%,33.1–40.3). Case definition 7 was the most specific case definition with a SP (99.8%, 99.4–100) and PPV (84.2%,61.2–94.7) but low SE (15.8%,9.3–24.5). Case definition 17 had a SE (75.3%, 65.7–83.3), SP (93.8%, 91.5–94.3) and PPV 43.7% (38.3–49.2). When we applied the most specific and most sensitive case definitions, we estimate the prevalence of eczema to be between 0.8 and 15.1%. Case definition 17 suggests an eczema prevalence estimate of 8.2% (8.08–8.21%). Conclusions We validated EMR-based eczema case definitions to estimate the prevalence of clinician-documented eczema. Future studies may choose to apply one or more of these definitions’ dependent on their studies objectives to inform disease surveillance as well as explore burden of illness or interventions related to eczema care in Canada.en_US
dc.identifier.citationAllergy, Asthma & Clinical Immunology. 2023 May 28;19(1):46
dc.identifier.citationAllergy, Asthma & Clinical Immunology. 2023 May 28;19(1):46
dc.identifier.citationAllergy, Asthma & Clinical Immunology. 2023 May 28;19(1):46
dc.identifier.citationAllergy, Asthma & Clinical Immunology. 2023 May 28;19(1):46
dc.identifier.doi10.1186/s13223-023-00785-4
dc.identifier.urihttps://doi.org/10.1186/s13223-023-00785-4
dc.identifier.urihttp://hdl.handle.net/1993/37365
dc.language.isoengen_US
dc.language.rfc3066en
dc.publisherBioMed Central (BMC)en_US
dc.rightsopen accessen_US
dc.rights.holderThe Author(s)
dc.subjecteczemaen_US
dc.subjectprimary health careen_US
dc.subjectelectronic health recordsen_US
dc.titleValidation of a primary care electronic medical records case definition for eczema: retrospective cross-sectional studyen_US
dc.typejournal articleen_US
local.author.affiliationRady Faculty of Health Sciences::Max Rady College of Medicine::Department of Family Medicineen_US
oaire.citation.issue1en_US
oaire.citation.startPage46en_US
oaire.citation.titleAllergy, Asthma & Clinical Immunologyen_US
oaire.citation.volume19en_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13223_2023_Article_785.pdf
Size:
1.24 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship